McGirr Alexander, Mohammed Safraz, Kurlan Roger, Cusimano Michael D
Injury Prevention Research, St-Michael's Hospital, University of Toronto, Toronto, ON, Canada; Department of Psychiatry, University of British Columbia, Vancouver, Canada.
J Neurol Sci. 2013 Oct 15;333(1-2):13-8. doi: 10.1016/j.jns.2013.06.024. Epub 2013 Sep 4.
Idiopathic normal pressure hydrocephalus (iNPH) is a syndrome that may be reversible by diversion of cerebrospinal fluid (CSF). It is increasingly recognized, and accordingly rates of CSF diversion are increasing despite the absence of level I evidence of efficacy, non-neglible rate of complications and an unclear natural history.
A total of 349 neurosurgeons, neurologists, geriatricians and neuropsychiatrists rated the perceived efficacy of CSF diversion, the duration of effect of CSF diversion, and the risk-benefit ratio of CSF diversion in iNPH. These physicians then rated the need for a randomized controlled trial (RCT) of CSF diversion in iNPH. Participants detailed their desired selection criteria and supportive testing for a RCT, and their preferred control group.
Physicians believe that there is uncertain efficacy of CSF diversion in iNPH, as well as the expected duration of this benefit and the risk-benefit ratio for patients. The greatest degree of uncertainty related to the long-term benefit of surgery. Accordingly, over 75% desire a RCT to determine the efficacy of CSF diversion in iNPH. Only 2.7% of participants believe a RCT of CSF diversion in iNPH is unethical. Patients without a shunt and a programmable valve in the 'off' setting were the preferred control groups.
A RCT of CSF diversion in iNPH is absent from the literature. The majority (>75%) of physicians involved in the diagnosis and treatment of iNPH believe a RCT is required to determine the efficacy, duration of efficacy and risk-benefit ratio of CSF diversion in iNPH.
特发性正常压力脑积水(iNPH)是一种通过脑脊液(CSF)分流可能可逆的综合征。尽管缺乏一级疗效证据、并发症发生率不可忽视且自然病史尚不明确,但该疾病越来越受到重视,相应地脑脊液分流率也在增加。
共有349名神经外科医生、神经科医生、老年病科医生和神经精神科医生对脑脊液分流在iNPH中的感知疗效、脑脊液分流效果的持续时间以及脑脊液分流的风险效益比进行了评分。然后,这些医生对iNPH中脑脊液分流随机对照试验(RCT)的必要性进行了评分。参与者详细说明了他们期望的RCT选择标准和支持性检测,以及他们首选的对照组。
医生们认为脑脊液分流在iNPH中的疗效不确定,以及这种益处的预期持续时间和患者的风险效益比。与手术长期益处相关的不确定性程度最高。因此,超过75%的人希望进行一项RCT来确定脑脊液分流在iNPH中的疗效。只有2.7%的参与者认为iNPH中脑脊液分流的RCT是不道德的。未使用分流器且处于“关闭”状态的可编程瓣膜的患者是首选的对照组。
文献中缺乏iNPH中脑脊液分流的RCT。参与iNPH诊断和治疗的大多数医生(>75%)认为需要进行一项RCT来确定脑脊液分流在iNPH中的疗效、疗效持续时间和风险效益比。